EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 68 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,848 | -61.8% | 2,400 | -52.9% | 0.00% | -50.0% |
| Q2 2023 | $99,144 | -30.9% | 5,100 | +0.9% | 0.01% | -40.0% |
| Q1 2023 | $143,467 | +226.1% | 5,057 | +197.5% | 0.01% | +233.3% |
| Q3 2022 | $44,000 | +388.9% | 1,700 | +655.6% | 0.00% | +200.0% |
| Q3 2020 | $9,000 | 0.0% | 225 | +74.4% | 0.00% | 0.0% |
| Q2 2018 | $9,000 | – | 129 | +1190.0% | 0.00% | – |
| Q2 2017 | $0 | -100.0% | 10 | -98.9% | 0.00% | -100.0% |
| Q4 2015 | $80,000 | +3.9% | 913 | -4.9% | 0.01% | 0.0% |
| Q2 2015 | $77,000 | -24.5% | 960 | -60.6% | 0.01% | -44.0% |
| Q1 2015 | $102,000 | – | 2,435 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |